Drugs / HST003
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05082831 Comparator | Nov 2021 → Dec 2022 | articular cartilage disorder | Histogen | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HST003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05082831 ↗ |
| Modality | Protein / enzyme biologic | “HST003 is human extracellular matrix secreted by human dermal fibroblasts under hypoxic conditions.” NCT05082831 ↗ |
| Route | Other | “HST003 will be injected into the microfracture defects (interstices) and fill the remainder of the defect to the cartilage margin following surgery.” NCT05082831 ↗ |